By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mersana Therapeutics, Inc. 

840 Memorial Drive
2nd Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-0020 Fax: n/a


Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.

Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.


November 2015


CEO: Anna Protopapas

Chief Medical Officer: Donal A. Bergstrom

Chief Business Officer: Eva M. Jack


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: Mersana


Company News
Mersana Adds To Antibody Drug Conjugate (ADC) Intellectual Property Portfolio With Issuance Of EP Patent 3/9/2017 6:09:31 AM
Mersana Presents New Data On Investigational Cancer Antibody Drug Conjugate At AACR Annual Meeting 3/2/2017 7:05:22 AM
Mersana Appoints Andrew A. F. Hack, M.D., Ph. D. To Board Of Directors 1/9/2017 11:44:36 AM
Mersana Appoints Andrew A. F. Hack, M.D., Ph. D. To Board Of Directors 1/6/2017 10:20:16 AM
Mersana Presents Updated Data On Investigational Cancer Antibody Drug Conjugate At World Conference On Lung Cancer 12/5/2016 12:46:03 PM
Mersana Announces FDA Clearance Of IND Application For Lead Antibody-Drug Conjugate XMT-1522 10/24/2016 12:05:18 PM
Booming Mersana Nabs Another $33 Million for a Total Take of $120 Million+ 6/16/2016 6:40:48 AM
Takeda (TKPYY) Wagers $1 Billion+ More on Mersana Therapeutics' Antibody Program 2/3/2016 7:50:49 AM
Mersana Therapeutics' Lead Immunoconjugate Continues To Demonstrate Complete Tumor Regressions In Multiple HER2-Expressing Breast Cancer Tumor Models 12/14/2015 7:42:20 AM
Mersana Therapeutics To Present Poster At The 2015 San Antonio Breast Cancer Symposium 12/1/2015 10:07:07 AM